New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 18, 2012
08:33 EDTFLMLFlamel announces FDA acceptance of NDA for undisclosed hospital-based product
Flamel Technologies SA announced that the U.S. FDA has accepted the company's New Drug Application, or NDA, for an undisclosed hospital-based product. Flamel has received a Prescription Drug User Fee Act, or PDUFA, date, the target date for the FDA to complete its review of the NDA, of May 31, 2013. For competitive reasons, the Company has decided not to identify the product at this time, but intends to provide additional information at a later date. Flamel believes that the product could have a significant impact on the company's revenue generation and favorably impact its progression to profitability. If approved by the FDA, the product is expected to generate approximately $25M-$35M or more in peak annual revenues, subject to the company being able to market and price the product successfully, of which there can be no assurance.
News For FLML From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 5, 2015
10:52 EDTFLMLFlamel confirms exclusive licensing agreement with Perrigo
Subscribe for More Information
09:56 EDTFLMLPerrigo and Flamel enter into exclusive licensing agreement for LiquiTime
Perrigo (PRGO) and Flamel (FLML) announced that they have entered into an exclusive licensing agreement for LiquiTime(R) extended release suspension. The technology will be utilized in the development of a portfolio of extended release suspension products intended for the U.S. OTC marketplace.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use